Inactive Instrument

News Synta Pharmaceuticals Corp. Nasdaq

Equities

US87162T2069

End-of-day quote Nasdaq Other stock markets
- ^USD	-

May. 07	Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	MT
May. 07	Madrigal Pharmaceuticals Q1 Loss Widens; Shares Fall Pre-Bell	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	May. 07	MT
Madrigal Pharmaceuticals Q1 Loss Widens; Shares Fall Pre-Bell	May. 07	MT
Transcript : Madrigal Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
Madrigal: Q1 Earnings Snapshot	May. 07	AQ
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates	May. 07	AQ
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Nonalcoholic Steatohepatitis Market to Observe Impressive Growth During the Forecast Period \| Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Eli Lilly and Company, Madrigal Pharmaceuticals	Apr. 26	AQ
Madrigal Statement on the Passing of Dr. Stephen Harrison	Apr. 24	AQ
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024	Apr. 24	AQ
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024	Apr. 23	AQ
BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective	Apr. 22	MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target	Apr. 22	MT
6 Stocks Positioned to Soar as Investors Focus on MASH	Apr. 22	AQ
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	Apr. 16	AQ
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing	Apr. 11	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing	Apr. 11	MT
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis	Apr. 10	AQ
Madrigal Pharmaceuticals Says Rezdiffra Available in US	Apr. 09	MT
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis	Apr. 09	AQ
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis	Apr. 09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Synta Pharmaceuticals Corp. Nasdaq

Equities

US87162T2069

Summary

Filters